What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence.
So what: Earlier this year, a phase 3 trial in...
What: After reporting that its marijuana-derived drug Epidiolex reduced the number of monthly seizures in patients with Lennox-Gastaut syndrome, GW Pharmaceuticals Plc shares jumped 10.6% last month, according to S&P Global Market Intelligence.
So what: Earlier this year, a phase 3 trial in...